China revises GMPs
This article was originally published in The Tan Sheet
China's State Food and Drug Administration proposes revised good manufacturing practices that would give nonprescription drug firms three years to implement changes once guidelines are issued. Guo Jingwu, director of drug safety in SFDA's Inspection Department, said June 2 at a conference in Shanghai that SFDA adopted the guidelines May 28 and expects to issue the document in June. China's Ministry Of Health is reviewing the guidance and will submit it to the World Trade Organization before releasing it. SFDA will give companies three years to implement changes, though firms that manufacture injection drugs and products on China's Essential Drug List will have two years. The GMP revision, a key goal for SFDA in 2010, is part of the agency's work to align China's pharmaceutical and medical device regulations with international standards (1"The Tan Sheet" March 8, 2010)
You may also be interested in...
China's State FDA insists it will align the country's pharmaceutical and medical device regulations with international standards. The question manufacturers have is, how soon
Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.
Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.